First pharmacological treatment for vitreomacular adhesion on the horizon

ThromboGenics has announced positive phase III results for ocriplasmin in the treatment of symptomatic vitreomacular adhesion (VMA).

Ophthalmoscope view of the retina of a patient's eye, showing a macular hole | SCIENCE PHOTO LIBRARY
Ophthalmoscope view of the retina of a patient's eye, showing a macular hole | SCIENCE PHOTO LIBRARY

Two randomised, double-blind, pivotal phase III trials (n=652) investigated intravitreal injection of ocriplasmin versus placebo in patients with macular hole or vitreomacular traction syndrome. In both studies, non-surgical resolution of focal VMA (the primary endpoint) occurred one month after a single injection of ocriplasmin.

"The new data confirm the effectiveness of ocriplasmin in patients with VMA. This is important given that symptomatic VMA is implicated in a range of retinal disorders," said Dr Peter Kaiser, Professor of Ophthalmology at the Cleveland Clinic, Lerner College of Medicine, in the US.

In the study in patients with vitreomacular traction syndrome, a significantly larger proportion of patients had resolution of VMA and associated visual symptoms in the ocriplasmin group than in the placebo group (29.8% versus 7.7%; p=0.001).

In the other study, among patients with a full thickness macular hole (FTMH), 40.6% of those treated with ocriplasmin achieved closure compared with 17% of those on placebo (p=0.004). In patients with FTMH under 250 micrometres, closure was observed in 58% of ocriplasmin-treated patients compared with 20% of patients receiving placebo.

Additionally, in both studies, the percentage of patients that had gained 3 or more lines in visual acuity after 6 months of treatment was around double in the treatment arm compared with the placebo arm.

Symptomatic VMA can lead to retinal distortion if left untreated. Invasive vitreoretinal procedures have been used but surgical complications, incomplete separation or vitreous removal and high cost have prompted investigation into a pharmacological approach. "I am confident that ocriplasmin will provide an effective and safe pharmacologic option which can be used to treat patients earlier," said Dr Kaiser.

Ocriplasmin (microplasmin) is a modified form of the endogenous protease plasmin. It is thought to act by degrading the fibronectin, laminin and type IV collagen fibres that adhere the vitreous to the retina, causing posterior vitreous detachment.

ThromboGenics recently announced that the EMA has accepted for review a Centralised Marketing Authorisation Application for ocriplasmin 2.5mg/ml solution for injection.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

New antibiotic prescribing guidance issued for pneumonia

New antibiotic prescribing guidance issued for pneumonia

NICE has published antimicrobial prescribing guidelines...

MIMS summary of NICE COPD guidance updated

MIMS summary of NICE COPD guidance updated

Prescribers can now consult the quick-reference MIMS...

Soft-mist inhaler now available as reusable device

Soft-mist inhaler now available as reusable device

Respimat is now available as a reusable inhaler that...

NICE recommends 'innovative' treatment for type I diabetes

NICE recommends 'innovative' treatment for type I diabetes

Dapagliflozin (Forxiga) has been approved for routine...